With our current findings describing improved VSV-p53 viruses and demonstrating long-term genomic stability of complex VSV recombinants encoding p53 transgenes, all of these data support further clinical development of VSV-p53 OVs as safe therapeutics for cancer. This evidence concerns the gene TP53 and cancer.